{"rows":[{"id":5910,"title":"Psilocybin-induced changes in electroencephalography link acute and long-term effects.","authors":"Nikolič M, Froese T, Mediano PAM, Koudelka V, Horáček J, Tylš F, Páleníček T.","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2026-09-04","publication_year":2026,"doi":"10.1177/02698811261473445","pubmed_id":"42698232","openalex_id":"https://openalex.org/W7208809041","source_url":"https://doi.org/10.1177/02698811261473445","substance_tags":"psilocybin","topic_tags":"Biomarkers,Healthy Volunteers","study_type":"Clinical Trial","source_name":"Europe PMC","publication_status":"published","date_added":"2026-09-06 01:20:05","last_checked":"2026-09-11 01:20:13","bibtex":null,"source_record_id":"PMID:42698232","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1177/02698811261473445","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42698232","source_url":"https://doi.org/10.1177/02698811261473445","doi":"10.1177/02698811261473445","pmid":"42698232","publication_date":"2026-09-04","importer_version":"2.1.3","text_redistributed":false}},{"id":5898,"title":"Differential effects of psilocybin derivatives on fentanyl-induced conditioned place preference in male and female mice.","authors":"Lovell TN, James PB, Hodgins SL, Johnson Noya S, Arner P, Bobadilla AC.","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2026-08-30","publication_year":2026,"doi":"10.1177/02698811261478613","pubmed_id":"42670231","openalex_id":"https://openalex.org/W7204852149","source_url":"https://doi.org/10.1177/02698811261478613","substance_tags":"psilocybin,psilocin","topic_tags":"Anxiety,Addiction,Animal Study,Adverse Events","study_type":"Animal Study","source_name":"Europe PMC","publication_status":"published","date_added":"2026-09-01 01:20:07","last_checked":"2026-09-06 01:20:16","bibtex":null,"source_record_id":"PMID:42670231","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1177/02698811261478613","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42670231","source_url":"https://doi.org/10.1177/02698811261478613","doi":"10.1177/02698811261478613","pmid":"42670231","publication_date":"2026-08-30","importer_version":"2.1.3","text_redistributed":false}},{"id":5895,"title":"A randomized crossover trial comparing the acute physiological and psychological effects of botanical formulations of oral psilocybin, oral psilocin, and sublingual psilocin.","authors":"Tai ML, Szigeti B, Downey AE, Aday JS, Fredenburg L, Sakai K, Molina C, Fernandes-Osterhold G, Bradley ER, Pantoni M, Moss R, Lightburn B, Plessow F, O'Donovan A, Woolley JD","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2026-08-29","publication_year":2026,"doi":"10.1177/02698811261478603","pubmed_id":"42668404","openalex_id":"https://openalex.org/W7204737036","source_url":"https://pubmed.ncbi.nlm.nih.gov/42668404/","substance_tags":"psilocybin,psilocin","topic_tags":"Pharmacology,Clinical Trial,Safety","study_type":"Clinical Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-08-31 01:20:05","last_checked":"2026-09-05 01:20:19","bibtex":null,"source_record_id":"PMID:42668404","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/42668404/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:42668404","source_url":"https://pubmed.ncbi.nlm.nih.gov/42668404/","doi":"10.1177/02698811261478603","pmid":"42668404","publication_date":"2026-08-29","importer_version":"2.1.3","text_redistributed":false}},{"id":5882,"title":"Beyond head-twitch response: Acute psilocybin affects spontaneous behaviors in rats in a dose-dependent manner.","authors":"Tiwari P, Jenkins BW, Moore CF, Zhou H, George T, Yaden DB, Weerts EM.","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2026-08-25","publication_year":2026,"doi":"10.1177/02698811261478600","pubmed_id":"42639976","openalex_id":"https://openalex.org/W7204167115","source_url":"https://doi.org/10.1177/02698811261478600","substance_tags":"psilocybin","topic_tags":"Mechanism of Action,Animal Study","study_type":"Animal Study","source_name":"Europe PMC","publication_status":"published","date_added":"2026-08-26 01:20:06","last_checked":"2026-09-01 01:21:00","bibtex":null,"source_record_id":"PMID:42639976","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1177/02698811261478600","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42639976","source_url":"https://doi.org/10.1177/02698811261478600","doi":"10.1177/02698811261478600","pmid":"42639976","publication_date":"2026-08-25","importer_version":"2.1.3","text_redistributed":false}},{"id":5865,"title":"Psilocybin-assisted psychotherapy for substance use disorders as a complex intervention: A systematic review of efficacy, mechanisms and psychotherapeutic frameworks.","authors":"Strika-Bruneau L, Elhssaini C, Fauvel B, Kervadec E, Bezo A, Amirouche A, Benyamina A, Romeo B.","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2026-08-17","publication_year":2026,"doi":"10.1177/02698811261473436","pubmed_id":"42609034","openalex_id":null,"source_url":"https://doi.org/10.1177/02698811261473436","substance_tags":"psilocybin","topic_tags":"Addiction,Mechanism of Action,Wellbeing,Clinical Trial,Systematic Review,Review Article,Safety,Drug Interactions","study_type":"Systematic Review","source_name":"Europe PMC","publication_status":"published","date_added":"2026-08-19 01:20:04","last_checked":"2026-08-24 01:20:14","bibtex":null,"source_record_id":"PMID:42609034","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1177/02698811261473436","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42609034","source_url":"https://doi.org/10.1177/02698811261473436","doi":"10.1177/02698811261473436","pmid":"42609034","publication_date":"2026-08-17","importer_version":"2.1.3","text_redistributed":false}},{"id":5771,"title":"Where is the sweet spot for psychedelic-enhanced fear extinction? An integrative quantitative synthesis of dose-effect patterns in rodent models.","authors":"Werle I, Probst MEC, Bertoglio LJ.","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2026-08-03","publication_year":2026,"doi":"10.1177/02698811261464979","pubmed_id":"42544550","openalex_id":null,"source_url":"https://doi.org/10.1177/02698811261464979","substance_tags":"psilocybin","topic_tags":"Anxiety,Receptor Pharmacology,Animal Study","study_type":"Animal Study","source_name":"Europe PMC","publication_status":"published","date_added":"2026-08-04 01:20:05","last_checked":"2026-08-10 01:20:18","bibtex":null,"source_record_id":"PMID:42544550","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1177/02698811261464979","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42544550","source_url":"https://doi.org/10.1177/02698811261464979","doi":"10.1177/02698811261464979","pmid":"42544550","publication_date":"2026-08-03","importer_version":"2.1.3","text_redistributed":false}},{"id":3147,"title":"Defining 'psychedelic'.","authors":"Ostrand AE, Nour MM, Timmermann C, Rosati A, Luan LX, Gomez-Emilsson A, Bornemann J, Greenway KT, Roseman L, R CH.","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2026-08-17","publication_year":2026,"doi":"10.1177/02698811261464986","pubmed_id":"42605589","openalex_id":null,"source_url":"https://doi.org/10.1177/02698811261464986","substance_tags":"psilocybin","topic_tags":"General","study_type":"Other","source_name":"Europe PMC","publication_status":"published","date_added":"2026-07-01 11:03:47","last_checked":"2026-08-24 01:20:18","bibtex":null,"source_record_id":"PMID:42605589","abstract_available":true,"abstract_source":"Europe PMC","abstract_source_url":"https://doi.org/10.1177/02698811261464986","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"Europe PMC","source_record_id":"PMID:42605589","source_url":"https://doi.org/10.1177/02698811261464986","doi":"10.1177/02698811261464986","pmid":"42605589","publication_date":"2026-08-17","importer_version":"2.1.3","text_redistributed":false}},{"id":2670,"title":"Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis.","authors":"Heekeren K, Neukirch A, Daumann J, Stoll M, Obradovic M, Kovar KA, Geyer MA, Gouzoulis-Mayfrank E","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2007-05-01","publication_year":2007,"doi":"10.1177/0269881107077734","pubmed_id":"17591658","openalex_id":"https://openalex.org/W2006900274","source_url":"https://pubmed.ncbi.nlm.nih.gov/17591658/","substance_tags":"psilocybin","topic_tags":"Healthy Volunteers","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:29","bibtex":null,"source_record_id":"PMID:17591658","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/17591658/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:17591658","source_url":"https://pubmed.ncbi.nlm.nih.gov/17591658/","doi":"10.1177/0269881107077734","pmid":"17591658","publication_date":"2007-05-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2653,"title":"Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.","authors":"Griffiths R, Richards W, Johnson M, McCann U, Jesse R","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2008-08-01","publication_year":2008,"doi":"10.1177/0269881108094300","pubmed_id":"18593735","openalex_id":"https://openalex.org/W2119738402","source_url":"https://pubmed.ncbi.nlm.nih.gov/18593735/","substance_tags":"psilocybin","topic_tags":"Wellbeing,Personality Change,Spirituality,Mystical Experience","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:29","bibtex":null,"source_record_id":"PMID:18593735","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/18593735/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:18593735","source_url":"https://pubmed.ncbi.nlm.nih.gov/18593735/","doi":"10.1177/0269881108094300","pmid":"18593735","publication_date":"2008-08-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2616,"title":"The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability.","authors":"Carhart-Harris RL, Williams TM, Sessa B, Tyacke RJ, Rich AS, Feilding A, Nutt DJ","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2011-11-01","publication_year":2011,"doi":"10.1177/0269881110367445","pubmed_id":"20395317","openalex_id":"https://openalex.org/W2051426845","source_url":"https://pubmed.ncbi.nlm.nih.gov/20395317/","substance_tags":"psilocybin","topic_tags":"Brain Imaging,Aging,Safety","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:28","bibtex":null,"source_record_id":"PMID:20395317","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/20395317/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:20395317","source_url":"https://pubmed.ncbi.nlm.nih.gov/20395317/","doi":"10.1177/0269881110367445","pmid":"20395317","publication_date":"2011-11-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2615,"title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.","authors":"Studerus E, Kometer M, Hasler F, Vollenweider FX","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2011-11-01","publication_year":2011,"doi":"10.1177/0269881110382466","pubmed_id":"20855349","openalex_id":"https://openalex.org/W1981740630","source_url":"https://pubmed.ncbi.nlm.nih.gov/20855349/","substance_tags":"psilocybin","topic_tags":"Anxiety,Safety,Adverse Events","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:28","bibtex":null,"source_record_id":"PMID:20855349","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/20855349/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:20855349","source_url":"https://pubmed.ncbi.nlm.nih.gov/20855349/","doi":"10.1177/0269881110382466","pmid":"20855349","publication_date":"2011-11-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2614,"title":"Salvia divinorum use and phenomenology: results from an online survey.","authors":"Sumnall HR, Measham F, Brandt SD, Cole JC","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2011-11-01","publication_year":2011,"doi":"10.1177/0269881110385596","pubmed_id":"20937616","openalex_id":"https://openalex.org/W2142154698","source_url":"https://pubmed.ncbi.nlm.nih.gov/20937616/","substance_tags":"psilocin","topic_tags":"Addiction,Receptor Pharmacology,Observational Study","study_type":"Observational Study","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:28","bibtex":null,"source_record_id":"PMID:20937616","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/20937616/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:20937616","source_url":"https://pubmed.ncbi.nlm.nih.gov/20937616/","doi":"10.1177/0269881110385596","pmid":"20937616","publication_date":"2011-11-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2613,"title":"Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice.","authors":"Halberstadt AL, Koedood L, Powell SB, Geyer MA","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2011-11-01","publication_year":2011,"doi":"10.1177/0269881110388326","pubmed_id":"21148021","openalex_id":"https://openalex.org/W2107441654","source_url":"https://pubmed.ncbi.nlm.nih.gov/21148021/","substance_tags":"psilocybin,psilocin","topic_tags":"Receptor Pharmacology,Animal Study","study_type":"Animal Study","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:28","bibtex":null,"source_record_id":"PMID:21148021","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/21148021/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:21148021","source_url":"https://pubmed.ncbi.nlm.nih.gov/21148021/","doi":"10.1177/0269881110388326","pmid":"21148021","publication_date":"2011-11-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2612,"title":"Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.","authors":"MacLean KA, Johnson MW, Griffiths RR","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2011-11-01","publication_year":2011,"doi":"10.1177/0269881111420188","pubmed_id":"21956378","openalex_id":"https://openalex.org/W2118739111","source_url":"https://pubmed.ncbi.nlm.nih.gov/21956378/","substance_tags":"psilocybin","topic_tags":"Personality Change,Creativity,Spirituality,Mystical Experience","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:28","bibtex":null,"source_record_id":"PMID:21956378","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/21956378/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:21956378","source_url":"https://pubmed.ncbi.nlm.nih.gov/21956378/","doi":"10.1177/0269881111420188","pmid":"21956378","publication_date":"2011-11-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2578,"title":"Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders.","authors":"Carhart-Harris RL, Brugger S, Nutt DJ, Stone JM","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2013-09-01","publication_year":2013,"doi":"10.1177/0269881113494107","pubmed_id":"23784738","openalex_id":"https://openalex.org/W1982429022","source_url":"https://pubmed.ncbi.nlm.nih.gov/23784738/","substance_tags":"psilocybin","topic_tags":"Depression,Pharmacology","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:28","bibtex":null,"source_record_id":"PMID:23784738","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/23784738/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:23784738","source_url":"https://pubmed.ncbi.nlm.nih.gov/23784738/","doi":"10.1177/0269881113494107","pmid":"23784738","publication_date":"2013-09-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2569,"title":"Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample.","authors":"Winstock AR, Kaar S, Borschmann R","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2014-01-01","publication_year":2014,"doi":"10.1177/0269881113513852","pubmed_id":"24284475","openalex_id":"https://openalex.org/W2006293429","source_url":"https://pubmed.ncbi.nlm.nih.gov/24284475/","substance_tags":"psilocybin","topic_tags":"Observational Study,Abuse Liability","study_type":"Observational Study","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:28","bibtex":null,"source_record_id":"PMID:24284475","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/24284475/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:24284475","source_url":"https://pubmed.ncbi.nlm.nih.gov/24284475/","doi":"10.1177/0269881113513852","pmid":"24284475","publication_date":"2014-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2568,"title":"Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision.","authors":"Hendricks PS, Clark CB, Johnson MW, Fontaine KR, Cropsey KL","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2014-01-01","publication_year":2014,"doi":"10.1177/0269881113513851","pubmed_id":"24399338","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/24399338/","substance_tags":"psilocybin","topic_tags":"Addiction","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:28","bibtex":null,"source_record_id":"PMID:24399338","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/24399338/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:24399338","source_url":"https://pubmed.ncbi.nlm.nih.gov/24399338/","doi":"10.1177/0269881113513851","pmid":"24399338","publication_date":"2014-01-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2555,"title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.","authors":"Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2014-11-01","publication_year":2014,"doi":"10.1177/0269881114548296","pubmed_id":"25213996","openalex_id":"https://openalex.org/W2122459973","source_url":"https://pubmed.ncbi.nlm.nih.gov/25213996/","substance_tags":"psilocybin","topic_tags":"Addiction,Receptor Pharmacology,Biomarkers,Safety","study_type":"Other","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:27","bibtex":null,"source_record_id":"PMID:25213996","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/25213996/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:25213996","source_url":"https://pubmed.ncbi.nlm.nih.gov/25213996/","doi":"10.1177/0269881114548296","pmid":"25213996","publication_date":"2014-11-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2545,"title":"Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.","authors":"Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2015-03-01","publication_year":2015,"doi":"10.1177/0269881114565144","pubmed_id":"25586396","openalex_id":"https://openalex.org/W2075238613","source_url":"https://pubmed.ncbi.nlm.nih.gov/25586396/","substance_tags":"psilocybin","topic_tags":"Addiction,Mechanism of Action,Receptor Pharmacology,Clinical Trial,Safety,Adverse Events","study_type":"Clinical Trial","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:27","bibtex":null,"source_record_id":"PMID:25586396","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/25586396/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:25586396","source_url":"https://pubmed.ncbi.nlm.nih.gov/25586396/","doi":"10.1177/0269881114565144","pmid":"25586396","publication_date":"2015-03-01","importer_version":"2.1.3","text_redistributed":false}},{"id":2544,"title":"Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population.","authors":"Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW","journal":"Journal of psychopharmacology (Oxford, England)","publication_date":"2015-03-01","publication_year":2015,"doi":"10.1177/0269881114565653","pubmed_id":"25586402","openalex_id":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/25586402/","substance_tags":"psilocybin","topic_tags":"Observational Study","study_type":"Observational Study","source_name":"PubMed","publication_status":"published","date_added":"2026-07-01 06:54:14","last_checked":"2026-08-09 08:28:27","bibtex":null,"source_record_id":"PMID:25586402","abstract_available":true,"abstract_source":"PubMed","abstract_source_url":"https://pubmed.ncbi.nlm.nih.gov/25586402/","abstract_redistributed":false,"text_rights_status":"unverified_not_redistributed","text_license_uri":null,"source_provenance":{"source_name":"PubMed","source_record_id":"PMID:25586402","source_url":"https://pubmed.ncbi.nlm.nih.gov/25586402/","doi":"10.1177/0269881114565653","pmid":"25586402","publication_date":"2015-03-01","importer_version":"2.1.3","text_redistributed":false}}],"total":153,"page":1,"per_page":20,"pages":8,"resource":"papers","filters":{"q":null,"author":null,"substances":["psilocybin","psilocin"],"topic":null,"study_type":null,"cited_doi":null,"sources":[],"publication_statuses":[],"year":null,"journal":"Journal of psychopharmacology (Oxford, England)","from":null,"to":null,"added_from":null,"added_to":null,"sort":"newly_added","page":1,"per_page":"20"}}